Genelux Corporation Reports $8.9 Million Net Loss in Q1 2026, No Revenue Generated

Genelux Corporation reported its financial results for the first quarter of 2026, revealing a net loss of $8.9 million, compared to a net loss of $7.5 million for the same period in 2025. The company did not generate any revenue during this quarter, consistent with its previous fiscal period. Total operating expenses increased to $9.2 million from $7.8 million year-over-year, driven primarily by higher research and development costs, which rose to $5.8 million from $4.7 million. General and administrative expenses also saw a slight increase, totaling $3.4 million compared to $3.1 million in the prior year.

In terms of financial position, Genelux reported total assets of $32.4 million as of March 31, 2026, a significant increase from $19.0 million at the end of 2025. This growth was largely attributed to an increase in cash, cash equivalents, and marketable securities, which rose to $26.3 million from $15.1 million. The company’s stockholders’ equity also improved, reaching $22.9 million, up from $11.5 million at the end of the previous year, following a successful underwritten offering of 6.7 million shares at $3.00 per share, which generated net proceeds of $18.5 million.

Operationally, Genelux continues to focus on its lead product candidate, Olvi-Vec, an oncolytic immunotherapy for cancer treatment. The company is engaged in ongoing clinical trials, including a Phase 1b/2 trial for small cell lung cancer and a Phase 2 trial for non-small cell lung cancer, both of which are being conducted in collaboration with Newsoara HYK Biopharmaceuticals Co., Ltd. As of the latest data review, preliminary results from these trials have shown promising outcomes, although the company has not yet commercialized any products.

The company’s financial outlook remains cautious, as it has incurred significant operating losses since its inception and continues to rely on external funding to support its operations. Genelux indicated that it expects its existing cash and securities to fund operations into the first quarter of 2027. However, the company has expressed uncertainty regarding its ability to raise additional funds or secure partnerships for commercialization, which could impact its future development plans. The management emphasized the need for substantial additional funding to support ongoing research and development activities and to navigate the complexities of clinical trials and regulatory approvals.